Jade Biosciences, Inc. (JBIO)
$13.42-4.14%Close
SELLCRISIS · day 28
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $438M
- Beta
- 1.45
- P/E (TTM)
- -4.88
- Short % float
- 49.90%
- Days to cover
- 11.3
- SI change
- +10.3%
- 1W
- +0.07%
- 1M
- -26.18%
- vs SPY 1W
- -0.35%
- vs SPY 1M
- -28.24%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 14
- VALUE
- 8
- GROWTH
- 47
- GARP
- 6
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC-29.5%
REV YoY-
ROE-49.1%
EPS YoY-
ROA-32.5%
GROSS0
OP0
NET0
[VALUATION]
P/E TTM-4.88
P/E FWD-
SECTOR PE20.34
INDUSTRY PE13.84
P/B1.86
P/FCF-
EV/EBITDA-4.54
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E0.14
ALTMAN Z-
CURR RATIO14.93
ND/EBITDA-
BETA1.45
Company news
FAQ
- What is LOPJLB’s current signal on JBIO?
- LOPJLB’s latest quantitative signal on Jade Biosciences, Inc. (JBIO) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is JBIO in?
- Jade Biosciences, Inc. (JBIO) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Jade Biosciences, Inc. (JBIO) do?
- Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. It develops JADE101, a monoclonal antibody to block the A PRoliferation Inducing Ligand protein, which is in phase 1 clinical trial. The company also develops JADE201 and JADE-003, which are in preclinical development stage. …